KRAS and lung carcinoma: Mutations in several oncogenes are well-characterized driver events in various cancers, e.g., mutations in KRAS G12 residue in pancreatic and lung cancer,3 BRAF V600 in melanoma,4 and the EGFR L858 in lung cancer.5